Key statistics
On Friday, Terns Pharmaceuticals Inc (430:FRA) closed at 6.85, -32.84% below its 52-week high of 10.20, set on Sep 10, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.45 |
---|---|
High | 6.85 |
Low | 6.45 |
Bid | 6.80 |
Offer | 6.85 |
Previous close | 6.55 |
Average volume | 182.00 |
---|---|
Shares outstanding | 84.40m |
Free float | 84.28m |
P/E (TTM) | -- |
Market cap | 616.12m USD |
EPS (TTM) | -1.31 USD |
Data delayed at least 15 minutes, as of Nov 08 2024 20:55 GMT.
More ▼
Announcements
- Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences
- Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
- Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Terns Announces Pricing of Upsized $150.15 Million Public Offering
- Terns Announces Proposed Public Offering
- Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity
- Terns Pharmaceuticals Reports Second Quarter 2024 Financial Results and Corporate Updates
- Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition
- Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual Scientific Sessions and Upcoming Conference Participation
- Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
More ▼